101 related articles for article (PubMed ID: 28753889)
1. The Association of Uromodulin Genotype with Renal Cancer Aggressiveness.
Trevisani F; Larcher A; Cinque A; Capitanio U; Ripa F; Vago R; Bettiga A; Benigni F; Carenzi C; Muttin F; Bertini R; Briganti A; Salonia A; Rampoldi L; Montorsi F
Eur Urol Focus; 2019 Mar; 5(2):262-265. PubMed ID: 28753889
[TBL] [Abstract][Full Text] [Related]
2. Uromodulin rs4293393 T>C variation is associated with kidney disease in patients with type 2 diabetes.
Kumar V; Yadav AK; Kumar V; Bhansali A; Jha V
Indian J Med Res; 2017 Nov; 146(Suppol):S15-S21. PubMed ID: 29578190
[TBL] [Abstract][Full Text] [Related]
3. GNAS1 (Gαs) gene T393C polymorphism and renal cell carcinoma risk in a North Indian population: a case-control study.
Arjumand W; Ahmad ST; Nafees S; Ali N; Rashid S; Seth A; Sultana S
Genet Test Mol Biomarkers; 2012 Sep; 16(9):1062-6. PubMed ID: 22931242
[TBL] [Abstract][Full Text] [Related]
4. Uromodulin levels associate with a common UMOD variant and risk for incident CKD.
Köttgen A; Hwang SJ; Larson MG; Van Eyk JE; Fu Q; Benjamin EJ; Dehghan A; Glazer NL; Kao WH; Harris TB; Gudnason V; Shlipak MG; Yang Q; Coresh J; Levy D; Fox CS
J Am Soc Nephrol; 2010 Feb; 21(2):337-44. PubMed ID: 19959715
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia and renal cell carcinoma: The influence of HIF1A+1772C/T functional genetic polymorphism on prognosis.
Ferreira M; Teixeira A; Maurício J; Lobo F; Morais A; Medeiros R
Urol Oncol; 2017 Aug; 35(8):532.e25-532.e30. PubMed ID: 28476527
[TBL] [Abstract][Full Text] [Related]
6. SPP1 and UMOD gene variants are synergistically associated with risk of renal stone disease.
Patel YP; Patel SG; Patel SB; Parikh A; Soni S; Srivastava R; Raval C; Raval MA; Nand Pandey S; Ganpule AP; Desai MR
Gene; 2023 May; 863():147264. PubMed ID: 36804854
[TBL] [Abstract][Full Text] [Related]
7. Study of Uromodulin Gene Polymorphism in Egyptian Patients with End-Stage Renal Disease.
Abdelsalam M; Motawea M; Kyrillos F; Abdel-Razik A; Zaki MES; Abdel-Wahab A
Saudi J Kidney Dis Transpl; 2021; 32(1):157-162. PubMed ID: 34145125
[TBL] [Abstract][Full Text] [Related]
8. Clinical, Genetic, and Urinary Factors Associated with Uromodulin Excretion.
Troyanov S; Delmas-Frenette C; Bollée G; Youhanna S; Bruat V; Awadalla P; Devuyst O; Madore F
Clin J Am Soc Nephrol; 2016 Jan; 11(1):62-9. PubMed ID: 26683887
[TBL] [Abstract][Full Text] [Related]
9. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
10. Genetic variations in microRNAs and the risk and survival of renal cell cancer.
Du M; Lu D; Wang Q; Chu H; Tong N; Pan X; Qin C; Yin C; Wang M; Zhang Z
Carcinogenesis; 2014 Jul; 35(7):1629-35. PubMed ID: 24681820
[TBL] [Abstract][Full Text] [Related]
11. The CASP8 -652 6N insertion/deletion promoter polymorphism is associated with renal cell carcinoma risk and metastasis.
de Martino M; Haitel A; Schatzl G; Klingler HC; Klatte T
J Urol; 2013 Aug; 190(2):717-22. PubMed ID: 23313206
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism rs4787951 in IL-4R contributes to the increased risk of renal cell carcinoma in a Chinese population.
Lin Y; Yuan Q; Qian F; Qin C; Cao Q; Wang M; Chu H; Zhang Z
Gene; 2019 Feb; 685():242-247. PubMed ID: 30472377
[TBL] [Abstract][Full Text] [Related]
13. The role of XRCC6 T-991C functional polymorphism in renal cell carcinoma.
Chang WS; Ke HL; Tsai CW; Lien CS; Liao WL; Lin HH; Lee MH; Wu HC; Chang CH; Chen CC; Lee HZ; Bau DT
Anticancer Res; 2012 Sep; 32(9):3855-60. PubMed ID: 22993329
[TBL] [Abstract][Full Text] [Related]
14. The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma.
Frey UH; Lümmen G; Jäger T; Jöckel KH; Schmid KW; Rübben H; Müller N; Siffert W; Eisenhardt A
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):759-63. PubMed ID: 16467086
[TBL] [Abstract][Full Text] [Related]
15.
Wang J; Liu L; He K; Gao B; Wang F; Zhao M; Zhang L; On Behalf Of The Chinese Cohort Study Of Chronic Kidney Disease C-Stride
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828293
[TBL] [Abstract][Full Text] [Related]
16. UMOD as a susceptibility gene for end-stage renal disease.
Reznichenko A; Böger CA; Snieder H; van den Born J; de Borst MH; Damman J; van Dijk MC; van Goor H; Hepkema BG; Hillebrands JL; Leuvenink HG; Niesing J; Bakker SJ; Seelen M; Navis G;
BMC Med Genet; 2012 Sep; 13():78. PubMed ID: 22947327
[TBL] [Abstract][Full Text] [Related]
17. Risk of renal cell carcinoma and polymorphism in phase I xenobiotic metabolizing CYP1A1 and CYP2D6 enzymes.
Ahmad ST; Arjumand W; Seth A; Nafees S; Rashid S; Ali N; Hamiza OO; Sultana S
Urol Oncol; 2013 Oct; 31(7):1350-7. PubMed ID: 22281432
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of vascular endothelial growth factor polymorphisms on the risk of renal cell carcinomas.
Xian W; Zheng H; Wu WJ
Genet Mol Res; 2015 Jul; 14(3):7634-42. PubMed ID: 26214443
[TBL] [Abstract][Full Text] [Related]
19. A single nucleotide polymorphism in the UMOD promoter is associated with end stage renal disease.
Chen T; Wang Q; Li G; Wang L
BMC Med Genet; 2016 Dec; 17(1):95. PubMed ID: 27938332
[TBL] [Abstract][Full Text] [Related]
20. HLA-DRB1*0101 and *0405 as protective alleles in Japanese patients with renal cell carcinoma.
Ozdemir E; Kakehi Y; Nakamura E; Kinoshita H; Terachi T; Okada Y; Yoshida O
Cancer Res; 1997 Feb; 57(4):742-6. PubMed ID: 9044854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
